Analyst initiated coverage on Arrowhead with a new price target
$ARWR
Biotechnology: Pharmaceutical Preparations
Health Care
Analyst initiated coverage of Arrowhead with a rating of Overweight and set a new price target of $88.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/14/2026 | $98.00 | Buy | Stifel |
| 5/1/2026 | $88.00 | Overweight | Analyst |
| 4/21/2026 | $100.00 | Equal-Weight → Overweight | Morgan Stanley |
| 6/5/2024 | $31.00 | Neutral | Goldman |
| 12/4/2023 | $29.00 | Buy | BofA Securities |
| 9/19/2023 | $33.00 | Neutral | Citigroup |
| 7/21/2023 | Outperform | TD Cowen | |
| 5/12/2023 | $40.00 | Outperform → Market Perform | SVB Securities |
8-K - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
S-8 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
10-Q - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
3 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 third quarter ended June 30, 2026.Webcast and Conference Call DetailsInvestors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call.For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BIe3d7a8269de14d348890ebe006a5b6a1. Once registered, you will receive th
REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the conditionPeople living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing their quality of lifeMarketing authorisation is supported by positive Phase 3 PALISADE study data, in which 25 mg REDEMPLO demonstrated an 80% reduction in triglycerides from baseline and an 83% reduction in the incidence of acute pancreatitis in a pooled analysis of patients using all doses of REDEMPLO compared with placeboArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that the European
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced its plan to host a 2026 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule (TRiM™) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company's clinical candidates and external key opinion leaders, who will discuss the respective disease areas and treatment landscapes. Part I of Arrowhead's 2026 Summer Series of R&D Webinars will focus on Arrowhead's cardiometabolic pipeline and will be held on June 29, 2026,
Stifel initiated coverage of Arrowhead with a rating of Buy and set a new price target of $98.00
Analyst initiated coverage of Arrowhead with a rating of Overweight and set a new price target of $88.00
Morgan Stanley upgraded Arrowhead from Equal-Weight to Overweight and set a new price target of $100.00
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 third quarter ended June 30, 2026.Webcast and Conference Call DetailsInvestors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call.For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BIe3d7a8269de14d348890ebe006a5b6a1. Once registered, you will receive th
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on May 7, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 second quarter ended March 31, 2026. Webcast and Conference Call Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BI94a3f6754bd3471e8e895704fb645ee5. Once registered, you will r
AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile), which holds multiple clinical-stage and late-stage program
SC 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600: S&P MidCap 400 constituent Ciena Corp. (NYSE:CIEN) will replace Dayforce Inc. (NYSE:DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE:ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effec
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. "Ken has been a valuable member of the Arrowhead team, and he retires at a time of great financial strength for the company. The finance organization that Ken built over the years is very capable and provides strong support to our ambitious development and commercialization plans.
NEW YORK, Jan. 22, 2025 /PRNewswire/ -- Guidewire Software Inc. (NYSE:GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE:B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27. S&P 500 constituent Apollo Global Management Inc. (NYSE:APO) is acquiring Barnes Group in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector January 27, 2025 S&P MidCap 400 Addition Guidewi